

25 October 2006

The Companies Section  
The Australian Stock Exchange Limited  
530 Collins Street  
MELBOURNE VIC 3000

Dear Sir/Madam

**Amended Substantial Holding Notice for Antisense Therapeutics Limited**

We enclose amended Form 604 "Notice of Change of Interests of Substantial Holder" which was lodged in April 2006 with respect to a holding in Antisense Therapeutics Limited by Polychip Pharmaceuticals Pty Ltd (Polychip) (a wholly owned subsidiary of Circadian Technologies Limited). This notice has been amended to include Syngene Limited's interest in Antisense Therapeutics – Polychip has a 42.38% interest in Syngene Limited, which has been disclosed in Circadian's annual reports since the listing of Antisense Therapeutics in 2001.

Yours faithfully

**Natalie Korchev**  
Company Secretary

Level 1, 10 Wallace Avenue,  
Toorak, Victoria 3142,  
Australia

P: +61 (3) 9826 0399

F: +61 (3) 9824 0083

**Circadian Technologies Limited**

ABN 32 006 340 567

[www.circadian.com.au](http://www.circadian.com.au)

**FORM 604**  
Corporations Act 2001

Section 671B

**NOTICE OF CHANGE OF INTERESTS OF SUBSTANTIAL HOLDER**  
*(AMENDMENT TO FORM 604 LODGED ON 11 APRIL 2006)*

To: **ANTISENSE THERAPEUTICS LIMITED**

ACN: **095 060 745**

**1. Details of substantial holder (1)**

Name: **POLYCHIP PHARMACEUTICALS PTY LTD (POLYCHIP) (A WHOLLY OWNED SUBSIDIARY OF CIRCADIAN TECHNOLOGIES LIMITED)**

ACN: **006 455 456**

There was a change in the interests  
of the substantial holder on **10/4/2006**

The previous notice was  
given to the company on **5/11/2003**

The previous notice was dated **5/11/2003**

**2. Previous and present voting power**

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

| Class of securities (4)      | Previous notice    |                  | Present notice     |                  |
|------------------------------|--------------------|------------------|--------------------|------------------|
|                              | Person's votes     | Voting power (5) | Person's votes     | Voting power (5) |
| <b>Ordinary:</b>             |                    |                  |                    |                  |
| Polychip                     | 72,436,800         | 20.39%           | 102,739,830        | 22.13%           |
| Syngene Limited <sup>A</sup> | <u>54,413,467</u>  | <u>15.30%</u>    | <u>54,413,467</u>  | <u>11.72%</u>    |
| <b>Total</b>                 | <b>126,850,267</b> | <b>35.69%</b>    | <b>157,153,297</b> | <b>33.85%</b>    |

<sup>A</sup> Polychip Pharmaceuticals Pty Ltd has a 42.38% interest in Syngene Limited and Syngene Limited owns 54,413,467 ordinary shares in Antisense Therapeutics Limited.

### 3. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

| Date of change | Person whose relevant interest changed | Nature of change (6)   | Consideration given in relation to change (7) | Class and number of securities affected | Person's votes affected (no. of shares) |
|----------------|----------------------------------------|------------------------|-----------------------------------------------|-----------------------------------------|-----------------------------------------|
| 10/4/06        | <b>Polychip Pharmaceuticals P/L</b>    | <b>Share Placement</b> | <b>\$0.033 per ordinary share</b>             | <b>Ordinary shares<br/>30,303,030</b>   | <b>30,303,030</b>                       |

### 4. Present relevant interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

| Holder of relevant interest                                                  | Registered holder of securities         | Person entitled to be registered as holder (8) | Nature of relevant interest (6) | Class and number of securities         | Person's votes     |
|------------------------------------------------------------------------------|-----------------------------------------|------------------------------------------------|---------------------------------|----------------------------------------|--------------------|
| <b>Polychip Pharmaceuticals Pty Ltd</b>                                      | <b>Polychip Pharmaceuticals Pty Ltd</b> | <b>Polychip Pharmaceuticals Pty Ltd</b>        | <b>Beneficial Owner</b>         | <b>Ordinary shares<br/>102,739,830</b> | <b>102,739,830</b> |
| <b>Syngene Limited</b><br><i>(Polychip has a 42.38% interest in Syngene)</i> | <b>Syngene Limited</b>                  | <b>Syngene Limited</b>                         | <b>Beneficial Owner</b>         | <b>Ordinary shares<br/>54,413,467</b>  | <b>54,413,467</b>  |

### 5. Changes in association

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

| Name and ACN (if applicable) | Nature of association |
|------------------------------|-----------------------|
| <b>Not applicable</b>        |                       |

### 6. Addresses

The addresses of persons named in this form are as follows:

| Name                                    | Address (Registered Office)                                   |
|-----------------------------------------|---------------------------------------------------------------|
| <b>Polychip Pharmaceuticals Pty Ltd</b> | <b>Rialto Towers, Level 23, 525 Collins Street, Melbourne</b> |
| <b>Circadian Technologies Limited</b>   | <b>Rialto Towers, Level 23, 525 Collins Street, Melbourne</b> |
| <b>Syngene Limited</b>                  | <b>Level 1, 10 Wallace Avenue, Toorak, Victoria</b>           |

Signed by:

Natalie Korchev  
Company Secretary  
25 October 2006